DFX Intelligence
Venture Capital Intelligence
Firms, funds, partners, companies and rounds from sworn filings, firm sites and announcements, kept as a graph with a date and a source on every edge. Facts, inferences and estimates are labelled as such. A fund target is never a close, GAV is never dry powder, and a round size is never an investor’s check.
Companies / Mediar Therapeutics, Inc.
Mediar Therapeutics, Inc.
Series BBoston, MABiotechnology
Facts
- Year of incorporation
- unknown
- Revenue range (Form D)
- Decline to Disclosesec.gov
- Rounds on record
- 3
- Disclosed raised
- $76.0Msum of rounds with a disclosed amount only
- Named investors
- 4
Financing history
3 rounds
- Jan 7, 2026Series B · $76.0M (disclosed)Amplitude Ventures (lead)Asahi Kasei Pharma Ventures (participant)ICG (lead)Alexandria Real Estate Trust (participant)Fact Press release wires (Business Wire, PR Newswire, GlobeNewswire public RSS) · “Mediar Therapeutics Announces Oversubscribed $76 Million Series B Financing and Clinical Advancement of First-in-Class Fibrosis Portfolio”
- Dec 10, 2025Form D equity offering · $37.8M (form d sold) · 18 investorsFact SEC EDGAR Form D data sets (quarterly) · “Mediar Therapeutics, Inc. filed Form D: $37,849,815 sold of $75,699,630, Biotechnology”
- Nov 18, 2022Form D equity offering · $85.0M (form d sold) · 17 investorsFact SEC EDGAR Form D data sets (quarterly) · “Mediar Therapeutics, Inc. filed Form D/A: $85,034,866 sold of $85,034,866, Biotechnology”
Investors on record
4 edges
- Alexandria Real Estate Trust round, participant Fact prnewswire.com
- Amplitude Ventures round, lead Fact prnewswire.com
- Asahi Kasei Pharma Ventures round, participant Fact prnewswire.com
- ICG round, lead Fact prnewswire.com
People
1 officers, 11 directors
- Rahul Ballal Executive Officer/Director sec.gov
- Andreas Jurgeit Director Fact
- Anja Konig Director Fact
- Cassidy Blundell Director Fact
- Maina Bhaman Director Fact
- Simon Sturge Director Fact
- Michael Baran Director Fact
- Meredith Fisher Director Fact
- Bharat Srinivasa Director Fact
- Allan Marchington Director Fact
- Adam Cotton Director Fact
- Marie-Claire Peakman Director Fact
Timeline
3
- Jan 7, 2026Mediar Therapeutics announced Series B of $76,000,000, led by Amplitude Ventures, ICGRound announced Fact Press release wires (Business Wire, PR Newswire, GlobeNewswire public RSS)
- Dec 23, 2025Mediar Therapeutics, Inc. filed Form D: $37,849,815 sold of $75,699,630, BiotechnologyForm D filed Fact SEC EDGAR Form D data sets (quarterly)
- Oct 22, 2024Mediar Therapeutics, Inc. filed Form D/A: $85,034,866 sold of $85,034,866, BiotechnologyForm D filed Fact SEC EDGAR Form D data sets (quarterly)
Evidence
29 observations
Every observation on this company
- Entity type: Corporation Dec 23, 2025 Fact SEC EDGAR Form D data sets (quarterly)
- Entity type: Corporation Oct 22, 2024 Fact SEC EDGAR Form D data sets (quarterly)
- Form D industry group: Biotechnology Dec 23, 2025 Fact SEC EDGAR Form D data sets (quarterly)
- Form D industry group: Biotechnology Oct 22, 2024 Fact SEC EDGAR Form D data sets (quarterly)
- Amendment: false Dec 23, 2025 Fact SEC EDGAR Form D data sets (quarterly)
- Amendment: true Oct 22, 2024 Fact SEC EDGAR Form D data sets (quarterly)
- Revenue range (Form D): Decline to Disclose Dec 23, 2025 Fact SEC EDGAR Form D data sets (quarterly)
- Revenue range (Form D): Decline to Disclose Oct 22, 2024 Fact SEC EDGAR Form D data sets (quarterly)
- Incorporated: overFiveYears Dec 23, 2025 Fact SEC EDGAR Form D data sets (quarterly)
- Incorporated: overFiveYears Oct 22, 2024 Fact SEC EDGAR Form D data sets (quarterly)
- Jurisdiction: DELAWARE Dec 23, 2025 Fact SEC EDGAR Form D data sets (quarterly)
- Jurisdiction: DELAWARE Oct 22, 2024 Fact SEC EDGAR Form D data sets (quarterly)
- Amount sold (Form D): $37.8M Dec 23, 2025 Fact SEC EDGAR Form D data sets (quarterly)
- Amount sold (Form D): $85.0M Oct 22, 2024 Fact SEC EDGAR Form D data sets (quarterly)
- Offering amount (Form D): $75.7M Dec 23, 2025 Fact SEC EDGAR Form D data sets (quarterly)
- Offering amount (Form D): $85.0M Oct 22, 2024 Fact SEC EDGAR Form D data sets (quarterly)
- Exemptions: 06b Dec 23, 2025 Fact SEC EDGAR Form D data sets (quarterly)
- Exemptions: 06b Oct 22, 2024 Fact SEC EDGAR Form D data sets (quarterly)
- First sale: 2025-12-10 Dec 23, 2025 Fact SEC EDGAR Form D data sets (quarterly)
- First sale: 2022-11-18 Oct 22, 2024 Fact SEC EDGAR Form D data sets (quarterly)
- Investors (Form D): 18 Dec 23, 2025 Fact SEC EDGAR Form D data sets (quarterly)
- Investors (Form D): 17 Oct 22, 2024 Fact SEC EDGAR Form D data sets (quarterly)
- Minimum investment (Form D): 0 Dec 23, 2025 Fact SEC EDGAR Form D data sets (quarterly)
- Minimum investment (Form D): 0 Oct 22, 2024 Fact SEC EDGAR Form D data sets (quarterly)
- Securities offered: equity Dec 23, 2025 Fact SEC EDGAR Form D data sets (quarterly)
- Securities offered: equity Oct 22, 2024 Fact SEC EDGAR Form D data sets (quarterly)
- Office address: 20 OVERLAND STREET, SUITE 520, BOSTON, MA, 02215 Dec 23, 2025 Fact SEC EDGAR Form D data sets (quarterly)
- Office address: 20 OVERLAND STREET, SUITE 520, BOSTON, MA, 02215 Oct 22, 2024 Fact SEC EDGAR Form D data sets (quarterly)
- Round announced: Series B $76,000,000 Jan 7, 2026 Fact Press release wires (Business Wire, PR Newswire, GlobeNewswire public RSS)